Cuvitru™ (immune globulin subcutaneous [human], 20% solution) – New drug approval
September 14, 2016 – Shire announced the FDA approval of Cuvitru (immune globulin subcutaneous [human], 20% solution), indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥ 2 years of age.
Top